A
Anupama Rao
Researcher at Great Ormond Street Hospital
Publications - 31
Citations - 619
Anupama Rao is an academic researcher from Great Ormond Street Hospital. The author has contributed to research in topics: Medicine & Haematopoiesis. The author has an hindex of 9, co-authored 27 publications receiving 373 citations. Previous affiliations of Anupama Rao include University of Milano-Bicocca & Great Ormond Street Hospital for Children NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Franco Locatelli,Michael B. Jordan,Carl E. Allen,Simone Cesaro,Carmelo Rizzari,Anupama Rao,Barbara A. Degar,Timothy P. Garrington,Julián Sevilla,Maria-Caterina Putti,Franca Fagioli,Martina Ahlmann,Jose-Luis Dapena Diaz,Michael J Henry,Fabrizio De Benedetti,Alexei Grom,Geneviève Lapeyre,Philippe Jacqmin,Maria Ballabio,Cristina de Min +19 more
TL;DR: Empalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis and was not associated with any organ toxicity.
Journal ArticleDOI
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Anupama Rao,Robert Kerrin Hills,Charles A. Stiller,Brenda Gibson,Siebold S. N. de Graaf,Ian Hann,Aengus O'Marcaigh,Keith Wheatley,David Webb +8 more
TL;DR: Analysis of population‐based data on 81 children with myeloid leukaemia of Down syndrome and experience in AML 10 and AML 12 trials concluded that future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease.
Journal ArticleDOI
Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
TL;DR: Combined treatment with daclizumab and infliximab is an effective therapeutic option for patients with steroid-refractory GVHD and seems to be associated with a low infection-related mortality compared with previous therapies.
Journal ArticleDOI
Blinatumomab for infant acute lymphoblastic leukemia.
Katherine Clesham,Vasudha Nandagudi Rao,Jack Bartram,P Ancliff,Sara Ghorashian,David O'Connor,David O'Connor,Vesna Pavasovic,Anupama Rao,Sujith Samarasinghe,Michelle Cummins,Andrea Malone,Katharine Patrick,Denise Bonney,Beki James,Brenda Gibson,Ajay Vora +16 more
TL;DR: This poster aims to raise awareness of the importance of routine check-up and follow-up care in the care of children and young people with life-threatening illnesses.
Journal ArticleDOI
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
E Louka,E Louka,Benjamin J. Povinelli,Benjamin J. Povinelli,Alba Rodriguez-Meira,Alba Rodriguez-Meira,Georgina Buck,Georgina Buck,Wei Xiong Wen,Wei Xiong Wen,Guanlin Wang,Guanlin Wang,Nikolaos Sousos,Nikolaos Sousos,Neil Ashley,Neil Ashley,Angela Hamblin,Booth Cag.,Booth Cag.,Anindita Roy,Natalina Elliott,Deena Iskander,J de la Fuente,Nicholas Fordham,Nicholas Fordham,Sorcha O’Byrne,Sarah Inglott,Ruggiero Norfo,Ruggiero Norfo,Mariolina Salio,Supat Thongjuea,Anupama Rao,Irene Roberts,Irene Roberts,Adam J. Mead,Adam J. Mead,Adam J. Mead +36 more
TL;DR: In this paper, single-cell RNA sequencing reveals marked heterogeneity of JMML hematopoietic stem/progenitor cells (HSPCs), including an aberrant Lin-CD34+CD38-CD90+CD45RA+ population.